Condition: Colo-rectal Cancer · Sponsor: NSABP Foundation Inc
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.
This description comes directly from the study's public registry record.
Department of Site and Study Management (DSSM) · 1-800-270-3165 · industry.trials@nsabp.org
Always discuss trial participation with your own doctor first.
| University of Florida | Gainesville, Florida, United States | Recruiting |
| University of Iowa - Holden Comprehensive Cancer Center | Iowa City, Iowa, United States | Recruiting |
| University of Kansas Cancer Center | Kansas City, Kansas, United States | Recruiting |
| Missouri Baptist | St Louis, Missouri, United States | Recruiting |
| First Health of the Carolinas | Pinehurst, North Carolina, United States | Recruiting |
| Allegheny General Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| Ballad Health Cancer Center - Kingsport | Kingsport, Tennessee, United States | Recruiting |
| Bon Secours St. Francis Medical Center | Midlothian, Virginia, United States | Recruiting |
| Virginia Commonwealth University - Massey | Richmond, Virginia, United States | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07058012